Analysts hail Akero's midphase NASH data as best in class Pfizer, BioNTech coronavirus vaccine candidate gins up antibodies in early trial More than two-thirds of trials hit by COVID-19 enrollment halts, with midstage tests the worst affected 2 months after launch, QurAlis nabs early ALS compounds from Eli Lilly Sumitomo merges U.S. biotechs to create oncology division Amylyx Pharmaceuticals nabs $30M for ALS, Alzheimer's work Evidation nets $45M to expand from virtual research into virtual treatment Featured Story | By Nick Paul Taylor Akero Therapeutics has shared more results from a phase 2a trial of its nonalcoholic steatohepatitis prospect efruxifermin. The trial found half of biopsied participants experienced a one-stage or greater improvement in fibrosis, prompting Jefferies analysts to hail the data as best in class and sending Akero’s share price soaring. read more |
| |
|---|
|
Top Stories By Eric Sagonowsky With the eyes of the world turned on the global COVID-19 vaccine race, Pfizer and its partner BioNTech have posted early positive data from one of their four candidates. With the results and others yet to come, the partners are prepping for a late-stage trial that could begin as early as this month. read more By Ben Adams Nearly 200 companies have stopped or delayed their trials over the pandemic, and life science analytics firm GlobalData has dug into the data and found the main culprit has been suspended enrollment. read more By Ben Adams In May, startup QurAlis got a $42 million series A toward targeting the genetic causes of two rare diseases: amyotrophic lateral sclerosis and genetically related frontotemporal dementia. read more By Nick Paul Taylor Sumitomo Dainippon Pharma has merged Tolero Pharmaceuticals and Boston Biomedical to form an oncology division with sites in Massachusetts and Utah. The U.S. unit, Sumitomo Dainippon Pharma Oncology Inc., will work with Sumitomo sites in Japan to advance a pipeline of cancer prospects. read more By Ben Adams After posting positive data that showed it could help slow down the degenerative ALS disease, Amylyx has been given a $30 million boost. read more By Conor Hale Evidation Health has secured $45 million to further expand its direct-to-person, virtual research platform, which already spans nearly 4 million participants. This includes plans to begin offering digital interventions and treatments. read more Enrollment Showcase | Sponsored by: University of Florida College of Pharmacy University of Florida precision medicine leaders highlight current knowledge and trends to advance the future of health care in this quarterly webinar series. Register today. |
| |
|---|
|
Resources Sponsored by: PRA Health Sciences Collaboration across the industry will be key to meeting the demands of the RACE Act and ensuring pediatric patients receive the care and treatments they need. Sponsored by: Systech Get an inside look… Merck shares its next-generation approach to supply chain protection with new digital platforms, including Blockchain. Sponsored by: Automation Anywhere Built on advances in Artificial Intelligence (AI), data mining, and information integration into various systems at 100% accuracy, the new era of intelligent automation is integral to life sciences for devising new treatments faster and at a lower expense. Sponsored by: Research Solutions Learn four ways to squeeze more value from your limited R&D resources. Sponsored by: BioAnalytix Download this eBook and Learn the Advanced Analytical Approaches for Improved Development of Cell and Gene Therapies Sponsored by: Blue Matter, strategic consultants in the life sciences White paper describing 7 keys to success for any biopharma company that is entering (or thinking about entering) Europe. Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. Drug Development Boot Camp® 2020 November 18-19, 2020 | Register now! Pre-Boot Camp training ongoing now. | COVID19 provisions – training will be on-site as normal. | New – may be possible for some individuals to access the training virtually in real time. | 